If you offer in vitro diagnostic tests or create testing for clinical studies, you’re aware of the free biotin interference issue. In samples from patients who take over-the-counter biotin supplements or biotin therapy, free biotin can cause false results with tests that use anti-biotin antibodies or streptavidin-based reagents.
Veravas now has a proprietary solution. VeraBind Biotin is a novel anti-biotin monoclonal antibody (mAb) that has a high binding affinity to conjugated biotin and a very low binding affinity to free biotin — nearly a million times lower than avidin and streptavidin. Use VeraBind Biotin to replace current anti-biotin antibodies or streptavidin-based reagents, and avoid the possibility of biotin interference.
In a free biotin competition study, it took 24,431 ng/mL free biotin (1.00 x 10-4 M) to suppress VeraBind Biotin’s binding by 50% as compared to only 0.028 ng/mL free biotin (1.15 x 10-10 M) with Streptavidin.
Since the FDA has requested that assay manufacturers test for biotin interference up to 3,000 ng/mL3, developers can have a high level of confidence whenusing VeraBind Biotin in their tests.
Veravas is transforming laboratory medicine with testing technology that strengthens quality of care for clinicians and patients. Our passionate and dedicated team can help address biotin-interference in your tests and assays. Get in touch with us to discuss how we can help you.Contact